Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Journal of Acquired Immune Deficiency Syndromes (1999)|March 1, 2005
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081)Laurence Morand-Joubert, Fabienne Marcellin, Odile Launay, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2003
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIsVéronique Joly, Diane Descamps, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2016
Abacavir has no prothrombotic effect on platelets in vitroYacouba L Diallo, Véronique Ollivier, Véronique Joly, et al.
Antiviral Therapy|January 17, 2014
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)David A Wohl, Chloe Orkin, Manuela Doroana, et al.
The Journal of Antimicrobial Chemotherapy|November 16, 2012
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trialCharlotte Charpentier, Véronique Joly, Lucile Larrouy, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2012
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcomeCharlotte Charpentier, Roland Landman, Cédric Laouénan, et al.
The Journal of Antimicrobial Chemotherapy|January 10, 2017
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control studyVincent Madelain, Minh P Le, Karen Champenois, et al.
Antiviral Therapy|August 26, 2009
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapyKeikawus Arastéh, Armin Rieger, Patrick Yeni, et al.
AIDS (London, England)|September 10, 2011
Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimenLucile Larrouy, Charlotte Charpentier, Roland Landman, et al.
Antiviral Therapy|October 9, 2009
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96Keikawus Arastéh, Patrick Yeni, Anton Pozniak, et al.
Pageof 7